Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer’s Disease ConferenceLatest findings from Eisai's robust Alzheimer's disease pipeline explore long-term treatment with lecanemab and estimated time savings over 10 years, safety and potential benefits of subcutaneous administration of lecanemab for initiation dosing
Oral and poster presentations also include data on the effects of lecanemab on soluble amyloid-β protofibrils and insights from real-world clinical practice studies, including the ALZ-NET Registry